Skip to main contentSkip to navigationSkip to search
HNSA (, %) SEK
Hansa Biopharma logotype

Hansa Biopharma Announces Upcoming Presentations at the 2019 American Transplant Congress

Regulatory information
Lund, Sweden, May 2, 2019 - Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that IDEFIRIX (imlifidase), the Company’s novel IgG-degrading enzyme, will be highlighted in three presentations at the upcoming 2019 American Transplant Congress (ATC), which will be held from June 1 – 5, 2019 in Boston, Massachusetts, USA.

In a plenary session on June 5, 2019 at 8:30AM ET, Stanley C. Jordan, M.D., Director of Kidney Transplantation and Transplant Immunology at the Kidney and Pancreas Transplant Center at Cedars-Sinai Medical Center in Los Angeles, will present “Three-year Outcomes of Highly-sensitized Kidney Transplant Recipients Desensitized with IgG Endopeptidase.”

The presentation will report follow up data from the U.S. investigator-initiated Phase 2 study of imlifidase for kidney transplantation in 16 highly sensitized patients. Results show excellent graft survival out to three years. Over the observed 31.9 person years, there were two graft losses, unrelated to imlifidase treatment, at 2.6 years and 3.2 years, conferring an incidence rate of 6.3 graft losses per 100 patient years. The graft survival for these patients undergoing desensitization was within the same range as for non-sensitized patients being transplanted with a kidney from a deceased donor1. One death, unrelated to imlifidase treatment and the kidney transplant, occurred 10 months after transplant. No patients had Donor Specific Antibodies (DSAs) post imlifidase treatment and DSA rebound out to 30 months was generally mild.

In an oral presentation on June 2, 2019 at 3:06pm ET, Robert A. Montgomery, M.D., Director, NYU Langone Transplant Institute, New York City, will present “Safety and Efficacy of Imlifidase in Highly-Sensitized Kidney Transplant Patients: Results from a Phase 2 Study.” The presentation will report complete Phase 2 results from Hansa’s Phase 2 Highdes study of imlifidase for kidney transplantation in highly sensitized patients. As previously reported, results show that imlifidase was well tolerated and enabled all patients to undergo transplantation resulting in good kidney function and graft survival. There were two graft losses due to graft failure unrelated to imlifidase treatment. In both cases the kidneys failed to recover after transplantation due to transplant recipient co-morbidities. The majority of the patients in this study represent the most highly sensitized patients on the organ donor waiting list by any standard.

In a poster session on June 2, 2019 at 6:00pm ET, Matthew J. Everly, Director of the Terasaki Research Institute in Los Angeles, will present “A Prognostic Drug Development Tool to Assess the Transplantability at the Time of Listing for Kidney Transplant Candidates.” The study reports on results of a machine learning based prognostic tool enabling a way to assess risk of death or long wait time at the time of listing. Simulations in highly sensitized patients demonstrate that transplant rates could be increased by 25% if there were a therapy to address the HLA antibody barrier.

The three abstracts are available on the ATC website: https://atcmeeting.org

References
1. https://optn.transplant.hrsa.gov

This is information that Hansa Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below at 08:00am CET on May 2, 2019.